C-terminal part of preprovasopressin and has no known function. 5 Vasopressin, with a half-life of only 24 minutes, 13 cannot serve as a reliable biomarker. 14 In addition, during pregnancy, placentally produced vasopressinase breaks down vasopressin, adding to difficulties in its measurement. 15 Copeptin has the advantage of remaining in circulation longer and can serve as a potential biomarker of preeclampsia. 16 Therefore, we sought to explore the association between copeptin and development of preeclampsia prospectively. To evaluate the potential of copeptin as a specific biomarker of preeclampsia, we also examined its relationship with gestational hypertension, gestational diabetes mellitus (GDM), and preterm birth.
Methods
The Calcium for Preeclampsia Prevention (CPEP) trial was a randomized clinical trial (1992) (1993) (1994) (1995) , where 4589 nulliparous women with singleton pregnancies were randomized to calcium supplements or placebo. 17, 18 Women were excluded if lost to follow-up or had incomplete information on outcomes (n=283), had a pregnancy loss (n=49), had an infant with chromosomal abnormality (n=1), or had no serum collected at baseline or samples were misdated (n=589). 19 We conducted a nested case control study selecting samples from the remaining 3667 women with and without certain pregnancy complications of interest. Case definitions of preeclampsia and gestational hypertension have been previously published. [18] [19] [20] See online-only Data Supplement for details on outcomes and covariates.
Selection
All cases of preterm preeclampsia (n=72), GDM (n=88), and preterm birth (n=87 without preeclampsia or diabetes mellitus) were included.
In addition, randomly selected cases of term preeclampsia (n=89) and gestational hypertension (n=114) were also included. The control group consisted of 136 women who were normotensive, normoglycemic, had no elevated proteinuria, and delivered a term infant who was not small for gestational age (SGA). Random selection was made while maintaining the distribution of participants from each site from among eligible participants.
Copeptin Measurement
Women provided a nonfasting blood sample before randomization and twice during follow-up between gestational weeks 26 and 29 and at approximately week 36. Women were randomized before 21 weeks and 6 days of gestation. Serum copeptin was measured by BRAHMS Immunoluminometric Assay (Thermo Scientific, Berlin, Germany) using coated-tubes after the methods of Morgenthaler et al. 14 Additional details on copeptin measurement can be found in the online-only Data Supplement. Our current analysis with measured copeptin consisted of 136 controls, 71 preterm preeclampsia, 98 term preeclampsia, 78 gestational hypertension (without GDM), 88 GDM (with 10 cases also having term preeclampsia), and 86 preterm deliveries without preeclampsia. This study was exempted from Institutional Review Board review and approval by the National Institutes of Health's Office of Human Subjects Research because of use of existing de-identified samples.
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Statistical Analysis
Crude and adjusted odds ratios and the 95% confidence intervals between copeptin and outcomes of interest were estimated by logistic regression. Measures were grouped into 3 gestational age periods of blood draw as originally designated by the trial. 17 To ensure that associations remained prospective in nature at later gestational ages, we excluded values measured after the date of diagnosis of preeclampsia or gestational hypertension. We also included only 1 measure per woman for each time window. (online-only Data Supplement). 
Downloaded from
The crude preeclampsia analysis was repeated dividing samples into 7 finer categories of gestational age. Mean log values and their SEs were plotted along with P values estimated using Wilcoxon rank-sum test. Finally, differences in copeptin measure by time until diagnosis were explored by pairing cases with control samples of similar gestational age at blood collection. For these analyses, samples measured at time of diagnosis or past time of diagnosis were grouped as 0 weeks from diagnosis. P values between mean levels of copeptin at each of these time points were calculated using Wilcoxon rank-sum test.
Results
Women with preeclampsia were significantly more likely to have higher body mass index and deliver lower birthweight babies (Table 1 ). Among women with preterm and term preeclampsia, 43 (61%) and 23 (24%) cases were severe, respectively. No significant differences in gestational age for the first and second blood draw by case status were found. In bivariate analyses, greater copeptin levels were significantly (P<0.05) associated with younger maternal age, black race, having never married, and not having private health insurance and clinical site (data not shown).
The median (interquartile range) of baseline log copeptin levels among preeclampsia cases and controls measured on average at 16 weeks of gestation were 3.85 (2.57-6.30) and 3.15 (2.17-4.72) pmol/L, respectively. Baseline levels were significantly and positively associated with risk of preeclampsia before its diagnosis (Table 2) . Each log unit increase in baseline copeptin was associated with increased risk of preeclampsia (odds ratio, 1.61), with similar associations for preterm and term cases. Adjustment for covariates slightly attenuated the associations and term preeclampsia risk was no longer significantly elevated, whereas preterm preeclampsia remained associated with copeptin. Repeating analyses excluding HELLP syndrome cases or preeclampsia cases with concurrent GDM did not affect results (data not shown). Higher copeptin levels were associated with increased risk of preterm birth not affected by preeclampsia; however, the association did not persist after adjustment for race (Table 2 ). In addition, among those who had SGA without preeclampsia (n=22, some with other complications: 6 with GH, 3 GDM, and 2 preterm), we found no difference in mean baseline levels of copeptin (geometric means of 2.91 for SGA versus 3.21 for non-SGA; P=0.46). Neither were differences observed in the risk of SGA (P>0.3) when compared with the controls at any time during pregnancy. Hence, differences observed for preeclampsia are not because of SGA or preterm birth. Copeptin was not associated with risks of gestational hypertension or GDM. The second and third copeptin measures were also associated with risk of preeclampsia ( Table 2) .
Because associations became progressively stronger closer to delivery, we investigated more finely divided categories of gestational age ( Figure 1 ) and associations by time to diagnosis ( Figure 2 ). As seen in Figure 1 , copeptin levels increased with gestational age among both cases and controls. Copeptin levels were generally higher for cases at each cross-sectional comparison than controls although some of the time points with sparse data did not reach statistical significance and the difference in mean log copeptin levels was smaller for term than for preterm cases. Mean copeptin levels increasingly differed by case, especially after 30 weeks of gestation. Mean levels did not differ by case until closer to time of diagnosis although differences were borderline significant (P=0.05) among preterm preeclampsia cases for samples taken from 9 to 14 weeks before diagnosis ( Figure 2 ). Samples at or after diagnosis (time 0 in Figure 2 ) strongly differed among both term and preterm cases. Copeptin levels had slightly stronger associations with severe than with mild preeclampsia (Table S1 in the onlineonly Data Supplement), but confidence intervals overlapped. Reclassification of definitions for hypertension, which include systolic blood pressure ≥140 mm Hg as a diagnostic criterion, also did not alter findings (Table S1 ). Finally, among 56 women with measured soluble fms-like tyrosine kinase-1 and placental growth factor before 22 weeks (42 of whom were preeclampsia cases), neither soluble fms-like tyrosine kinase-1 (r=0.10; P=0.45) or placental growth factor (r=−0.08; P=0.54) was correlated with copeptin measures nor significant correlations were observed at later gestational age (data not shown).
Discussion
Copeptin is a biomarker of arginine vasopressin, which acts on multiple systems to increase blood pressure and water retention. As a potential biomarker of preeclampsia, we prospectively evaluated copeptin levels among women who consequently developed preeclampsia and other pregnancy complications. Higher copeptin concentrations, measured before recognition of clinical disease, were associated with increased preeclampsia risk. Levels of copeptin increased across gestation regardless of preeclampsia case status but differed more markedly by case status closer to the time of diagnosis. Copeptin was not associated with GDM or gestational hypertension apart from preeclampsia, suggesting that it was specific to development of preeclampsia.
Vasopressin secretion and metabolism are altered in normal pregnancy, with a rise in secretion in early pregnancy. 6 Vasopressinase produced by the placenta increases dramatically during pregnancy, leading to increased vasopressin clearance through cleavage of vasopressin. 21 In fact, vasopressin is cleared 3 to 4× faster after midgestation but plasma levels are maintained, suggesting increased production rates. 22 Our observation that copeptin increases during gestation supports copeptin as a good biomarker for vasopressin secretion.
Vasopressin function is regulated by 3 receptor subtypes. 5 Although the V1a receptor function is suspected to play a role in hypertension, studies have not been able to find strong evidence. 23 Rather, decline in kidney function has more recently been found to be associated with vasopressin via measurement of copeptin levels in large epidemiological studies of nonpregnant individuals. 23 Multiple animal studies suggest that vasopressin's link with kidney function is causal 23 ; for instance, blocking vasopressin V1a or V2 receptors protects the deterioration of kidney function in rat models for nephropathy.
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Figure 1. Mean log copeptin levels (±SE) during gestational age for preeclampsia (PE) cases diagnosed before (A) and after (B) 37 weeks when compared with controls in the Calcium for Preeclampsia Prevention study. Conversely, administration of desmopressin, a powerful V2-receptor agonist, in rats and humans increases glomerular filtration rate and urinary albumin excretion. 26 In our pregnancy observations, it would seem women with gestational hypertension (ie, those who avoid kidney damage despite elevated blood pressure) do not overly secrete vasopressin above and beyond that of normal pregnancy. This once again confirms the differences in pathophysiology of the 2 conditions. 3 Among women who come to be diagnosed with preeclampsia, copeptin may serve as an early marker of the possible effect on renal function.
Studies measuring vasopressin directly in human pregnancy have not been conclusive. Risberg et al 27 found nonsignificantly higher levels of plasma vasopressin in weeks 12 and 24 of gestation and lower concentrations among mild preeclampsia cases at 36 weeks. Yet another study observed decreases in pregnancy, possibly because of vasopressinase metabolism. 28 Our findings using copeptin as a more stable biomarker of vasopressin provide a more accurate picture of vasopressin in pregnancy and in association with preeclampsia.
Few studies have measured copeptin with regards to preeclampsia. [29] [30] [31] [32] The first study observed significant differences in copeptin levels between 64 preeclampsia cases and 32 normotensive controls, but authors provided no information on time of preeclampsia diagnosis and cases may have been diagnosed before blood sampling. 31 Three other studies have also observed increased maternal copeptin among preeclampsia cases. 29, 30, 32 Santillan et al 32 prospectively observed a significant difference in copeptin levels beginning in the first trimester between 20 preeclampsia cases and 26 controls. They also observed using an animal model that infusion of vasopressin during pregnancy in mice leads to the clinical phenotypes observed in preeclampsia. 32 Our findings remain novel with regards to investigating the prospective association in a larger sample of preeclampsia cases and including other pregnancy complications.
Vasopressin affects glucose homeostasis. 33 Epidemiological evidence have observed associations between elevated copeptin levels and increased risk of incident type 2 diabetes mellitus. 16, 34 Despite these findings, our study showed no association between copeptin and risk of GDM. A lack of association has also been observed in another study conducted at delivery. 35 We add to these findings that copeptin levels do not differ before diagnosis of GDM.
To our knowledge, our study is the largest study to date investigating copeptin levels during pregnancy with risk of multiple pregnancy complications. Prospective measurements allowed for investigations into the effect of gestational age and associations in relation to timing of diagnosis. The inclusion of only healthy primiparas may preclude generalizability of results for cases of recurrent preeclampsia. Also, we did not have sufficient numbers of cases of SGA without preeclampsia (n=22) to rule out an independent contribution of SGA completely. In addition, despite the prospective nature of the study, we cannot decipher whether elevation in vasopressin secretion was secondary to endothelial dysfunction caused by placental disease because angiogenic factors were measured at the same time as copeptin. Our limited observation that copeptin was not correlated with measured angiogenic factors suggests that copeptin may provide additional information. A good biomarker for preeclampsia remains elusive and even angiogenic factors, such as soluble endoglin and soluble fmslike tyrosine kinase-1, both minimally affect prediction when examined against other clinical risk factors.
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Perspectives
Copeptin levels are elevated before diagnosis of preeclampsia. Levels progressively increase throughout pregnancy among normal pregnant women but significantly higher levels were observed only among women who develop preeclampsia and not for cases of gestational hypertension or GDM. Our observations add to the understanding of the role of vasopressin on the pathophysiology of preeclampsia. 
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What Is New?
• Maternal serum levels of copeptin, a biomarker for vasopressin, rise before clinical diagnosis of preeclampsia. Early pregnancy levels did not differ for other pregnancy complications, such as gestational diabetes mellitus or gestational hypertension without proteinuria, or for preterm birth not complicated by PE, suggesting that copeptin may serve as a specific biomarker for preeclampsia. Copeptin levels also rose as gestational age increased. This observation agrees with what has been shown for levels of vasopressin during pregnancy.
What Is Relevant?
• Because copeptin serves as a stable biomarker for vasopressin, our findings indicate that vasopressin may be dysregulated in cases of preeclampsia before its clinical diagnosis. Copeptin is associated with declining renal function in nonpregnant populations and this supports the notion that vasopressin is important in development of preeclampsia.
Summary
We investigated whether maternal serum copeptin, a biomarker for the antidiuretic hormone arginine vasopressin, differed in pregnancies complicated by preeclampsia, gestational hypertension, and gestational diabetes mellitus when compared with uncomplicated pregnancies using stored samples from the Calcium for Preeclampsia Prevention trial (1992) (1993) (1994) (1995) . Baseline copeptin levels at mean 16 weeks of gestation were positively associated with increased risk of preeclampsia even after accounting for maternal age, race, body mass index, insurance status, marital status, current smoking, and clinical site. Associations were stronger among cases diagnosed before 37 weeks of gestation, and no associations were found for gestational diabetes mellitus or gestational hypertension. Our findings demonstrate that copeptin levels are elevated in pregnant women before diagnosis of preeclampsia with elevation specific to this pregnancy complication rather than hypertension alone. The title contained a typo in "Increased levels of copeptin before clinical diagnosis of preelcampsia." It has now been corrected to read, "Increased levels of copeptin before clinical diagnosis of preeclampsia." Table S1 . Risk of PE by severity and by using contemporary definitions per log unit increase in baseline copeptin measured before 22 age, race, BMI, current smoking, married, private insurance, and clinical site † 12 severe PE cases met criteria for both severe hypertension and proteinuria ‡ Updated definition of PE based on both systolic and diastolic blood pressure cutoffs (140/90 mmHg). Six normal controls had gestational hypertension after reclassification. Five cases of preterm PE and 14 term cases were added (from previously preterm, GDM, gestational hypertension, gestational proteinuria groups.)
Novelty and Significance
